Literature DB >> 18609676

Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Peter-Laszlo Lakatos, Laszlo Lakatos.   

Abstract

The risk of colorectal cancer for any patient with ulcerative colitis is known to be elevated, and is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. Risk factors for cancer include extent and duration of ulcerative colitis, primary sclerosing cholangitis, a family history of sporadic colorectal cancer, severity of histologic bowel inflammation, and in some studies, young age at onset of colitis. In this review, the authors discuss recent epidemiological trends and causes for the observed changes. Population-based studies published within the past 5 years suggest that this risk has decreased over time, despite the low frequency of colectomies. The crude annual incidence rate of colorectal cancer in ulcerative colitis ranges from approximately 0.06% to 0.16% with a relative risk of 1.0-2.75. The exact mechanism for this change is unknown; it may partly be explained by the more widespread use of maintenance therapy and surveillance colonoscopy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609676      PMCID: PMC2725331          DOI: 10.3748/wjg.14.3937

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  97 in total

Review 1.  Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.

Authors:  P D Collins; C Mpofu; A J Watson; J M Rhodes
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  Review article: colorectal carcinoma and inflammatory bowel disease.

Authors:  J Eaden
Journal:  Aliment Pharmacol Ther       Date:  2004-10       Impact factor: 8.171

3.  Location and age at onset of colorectal cancer in Hungarian patients between 1993 and 2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary.

Authors:  Peter Fuszek; Henrik Csaba Horvath; Gabor Speer; Janos Papp; Petra Haller; Simon Fischer; Judit Halasz; Balazs Jaray; Eszter Szekely; Zsuzsanna Schaff; Andras Papp; Attila Bursics; Laszlo Harsanyi; Peter Lukovich; Peter Kupcsulik; Erika Hitre; Peter Laszlo Lakatos
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

4.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis.

Authors:  Ralf Kiesslich; Martin Goetz; Katharina Lammersdorf; Constantin Schneider; Juergen Burg; Manfred Stolte; Michael Vieth; Bernhard Nafe; Peter R Galle; Markus F Neurath
Journal:  Gastroenterology       Date:  2007-01-31       Impact factor: 22.682

7.  Inflammatory bowel disease is not associated with an increased risk of lymphoma.

Authors:  J D Lewis; W B Bilker; C Brensinger; J J Deren; D J Vaughn; B L Strom
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

8.  Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer.

Authors:  Megan M Garrity-Park; Edward V Loftus; Sandra C Bryant; William J Sandborn; Thomas C Smyrk
Journal:  Am J Gastroenterol       Date:  2008-02       Impact factor: 10.864

9.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years.

Authors:  Z Maratka; J Nedbal; J Kociánová; J Havelka; J Kudrmann; J Hendl
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

View more
  135 in total

Review 1.  MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.

Authors:  Lily P H Yang; Paul L McCormack
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.

Authors:  Gabriela Schiechl; Bernhard Bauer; Ivan Fuss; Sven A Lang; Christian Moser; Petra Ruemmele; Stefan Rose-John; Markus F Neurath; Edward K Geissler; Hans-Jürgen Schlitt; Warren Strober; Stefan Fichtner-Feigl
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

3.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

4.  New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

Authors:  Charles A Sninsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 5.  A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects.

Authors:  Harold Tjalsma; Annemarie Boleij; Julian R Marchesi; Bas E Dutilh
Journal:  Nat Rev Microbiol       Date:  2012-06-25       Impact factor: 60.633

Review 6.  Recent advances in understanding ulcerative colitis.

Authors:  Antonio Di Sabatino; Paolo Biancheri; Laura Rovedatti; Thomas Thornton Macdonald; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2011-11-09       Impact factor: 3.397

Review 7.  Colorectal Cancer in Inflammatory Bowel Disease.

Authors:  Ryan W Stidham; Peter D R Higgins
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

8.  Association between IL-4 -589C>T polymorphism and colorectal cancer risk.

Authors:  Qiang Li; Qian Wang; Xiaoyan Xu; Songtao Ren; Li Wang
Journal:  Tumour Biol       Date:  2013-11-12

9.  Establishing the colitis-associated cancer progression mouse models.

Authors:  Haiming Zheng; Zhanjun Lu; Ruhua Wang; Niwei Chen; Ping Zheng
Journal:  Int J Immunopathol Pharmacol       Date:  2016-09-30       Impact factor: 3.219

10.  DNA methylome and transcriptome alterations and cancer prevention by curcumin in colitis-accelerated colon cancer in mice.

Authors:  Yue Guo; Renyi Wu; John M Gaspar; Davit Sargsyan; Zheng-Yuan Su; Chengyue Zhang; Linbo Gao; David Cheng; Wenji Li; Chao Wang; Ran Yin; Mingzhu Fang; Michael P Verzi; Ronald P Hart; Ah-Ng Kong
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.